Rosanne Dunn
Directeur Technique/Scientifique/R&D chez HaemaLogiX Pty Ltd.
Profil
Rosanne Dunn is the founder of Immune System Therapeutics Ltd., which was founded in 2001.
She is currently the Chief Scientific Officer & Director at HaemaLogiX Pty Ltd.
Postes actifs de Rosanne Dunn
| Sociétés | Poste | Début |
|---|---|---|
HaemaLogiX Pty Ltd.
 HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Rosanne Dunn
| Sociétés | Poste | Fin |
|---|---|---|
Immune System Therapeutics Ltd.
 Immune System Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Immune System Therapeutics Ltd. engages in the development and commercialization of monoclonal antibodies to treat human blood cancers. The company was founded by Alan Liddle and Rosanne Dunn and is headquartered in Ultimo, Australia. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Immune System Therapeutics Ltd.
Immune System Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Immune System Therapeutics Ltd. engages in the development and commercialization of monoclonal antibodies to treat human blood cancers. The company was founded by Alan Liddle and Rosanne Dunn and is headquartered in Ultimo, Australia. | Health Technology |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Health Technology |